Enobosarm 9 mg is being developed for the targeted treatment of androgen receptor positive and estrogen receptor positive metastatic breast cancer: At the
Enobosarm 3 mg is being developed for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer: GTx continues to evaluate whether data from the POWER trials are sufficient to support a filing of a Marketing Authorization Application (MAA) with the
GTx-758 (Capesaris®) is being studied for secondary hormonal therapy in men with castration-resistant prostate cancer and, potentially, as a secondary hormonal treatment for advanced prostate cancer used in combination with ADT: GTx continues to enroll patients in an open-label, Phase 2 clinical study of GTx-758 to treat men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) and is evaluating the safety and efficacy of two doses (125 mg and 250 mg oral daily dosing) of GTx-758. The primary endpoint of the study is the proportion of patients with a = 50% decline from baseline in serum PSA by Day 90. Enrollment in the 125 mg arm has been completed and, after a pre-specified safety review by the independent Data Safety Monitoring Board identified no safety concerns, the Company commenced enrollment in the 250 mg arm.
Second Quarter and Six Months 2014 Financial Results
The net loss for the quarter ended
Research and development expenses for the quarter ended
About enobosarm (GTx-024) 9 mg
Enobosarm 9 mg, an oral selective androgen receptor modulator, is being studied for the targeted treatment of androgen receptor positive and estrogen receptor positive metastatic breast cancer. In preclinical and clinical studies, androgens suppress breast cancer growth. Prior studies have shown that women with metastatic breast cancer who have been previously treated with tamoxifen and whose cancer has progressed have responded to treatment with non-selective androgens, with overall response rates ranging from 20 to 60 percent. Although these non-selective androgens have been used to treat breast cancer, the unwanted virilizing side effects, including facial and body hair, enlargement of voice box, acne, and edema have limited their widespread clinical use. GTx believes that a selective androgen receptor modulator, like enobosarm, by targeting the androgen receptor in metastatic breast cancer, has the potential to provide clinical benefit to women with advanced breast cancer by treating their disease while minimizing the unwanted masculinizing side-effects associated with steroidal androgens. Furthermore, unlike steroidal androgens, enobosarm cannot be converted to an estrogen that could be detrimental in breast cancer. Additionally, women with metastatic breast cancer receiving treatment with enobosarm may receive the benefit of increased lean body mass, reduction in fat mass and improvement in physical function.
In the enobosarm 9 mg Phase 2 proof-of-concept, open-label clinical trial in the US, we enrolled 22 postmenopausal women with advanced breast cancer to assess clinical benefit response after six months of enobosarm 9 mg treatment, which was defined as those women receiving treatment who have demonstrated (i) a complete response (disappearance of all targeted lesions), (ii) a partial response (at least a 30 percent decrease in the sum of the diameters of the targeted lesions), or (iii) stable disease (no disease progression from baseline). Of the 22 patients enrolled in the study, a total of 20 patients had one or more scheduled assessments for determination of clinical benefit. The primary endpoint was assessed in 17 AR positive patients, with 6 patients demonstrating clinical benefit at six months, exceeding the pre-defined statistical threshold requiring that at least 3 of 14 patients with an AR positive metastatic lesion demonstrate clinical benefit. A total of 7 patients achieved clinical benefit at six months, which includes one patient whose AR status could not be determined. The results also demonstrated that, after a median duration on study of 81 days, 41 percent of all patients (9/22) achieved clinical benefit as best response and also had increased prostate specific antigen, or PSA, which appears to be an indicator of AR activity. The 7 patients achieving clinical benefit (which included 6 of the 17 patients with AR positive metastatic lesions, or 35 percent) had stable disease. No confirmed complete or partial responses have been observed in the study, although 3 patients currently remain on study past 270 days as their disease has continued to remain stable. Enobosarm was well tolerated. The most common adverse events, or AEs, reported were pain, fatigue, nausea, hot flash/night sweats, and arthralgia. The majority of AEs were Grade 1. There were two serious adverse events, or SAEs, reported during the study. Only one of the SAEs, bone pain of the chest cage, was assessed as possibly related to enobosarm.
About enobosarm (GTx-024) 3 mg
Enobosarm 3 mg, an oral selective androgen receptor modulator, is being developed for the prevention and treatment of muscle wasting in patients with advanced NSCLC. Following GTx’s announcement in
Enobosarm 3 mg demonstrated a statistically significant effect versus placebo on the primary endpoint of physical function through Day 84 in the POWER 1 clinical trial as assessed by continuous variable analysis, as pre-specified in our statistical analysis plan for the
In a meeting with
Enobosarm was well tolerated in both POWER trials. Although only minor differences in adverse events were observed between the groups with enobosarm 3 mg and placebo in the POWER1 and POWER2 trials, there were notable differences in the adverse event profiles between studies, with anemia and other hematologic toxicities being more prevalent in the POWER2 (platinum plus non-taxane) clinical trial. Survival was assessed as another safety endpoint to determine that enobosarm treatment did not adversely affect survival. A final analysis for survival was performed following 450 deaths in patients in both studies, which occurred in June of 2014. There were no statistical differences in survival between subjects in the placebo and enobosarm arms.
GTx-758, an oral nonsteroidal selective estrogen receptor alpha agonist, is being studied for secondary hormonal therapy in men with castration-resistant prostate cancer and, potentially, as a secondary hormonal treatment for advanced prostate cancer used in combination with ADT. GTx is enrolling an open-label, Phase 2 clinical study of GTx-758 to treat men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC). GTx-758 has previously demonstrated the ability to increase the production of a protein called sex hormone binding globulin (SHBG) that binds testosterone and thereby reduces free testosterone. The Phase 2 study is evaluating the safety and efficacy of two doses (125 mg and 250 mg oral daily dose) of GTx-758. The primary endpoint of the study is the proportion of patients with a = 50% decline from baseline in serum PSA by Day 90. Other key endpoints include SHBG and total and free testosterone levels, as well as prostate cancer progression, in the study subjects. In addition, the clinical study is evaluating the ability of GTx-758 to treat certain estrogen deficiency side-effects associated with LHRH agonists, such as hot flashes, bone loss, and insulin resistance.
Enrollment in the 125 mg arm has been completed without any incidences of venous thromboembolic events (VTEs) and, after a pre-specified safety review by the independent Data Safety Monitoring Board, the Company is now enrolling subjects in the 250 mg arm. Based upon the observed safety and efficacy in the 125 mg arm and with no safety issues having been observed in the first ten metastatic patients enrolled in the 250 mg arm, the Company is enrolling the remainder of the 250 mg arm with both high risk non-metastatic and metastatic CRPC patients, with the expectation that enrollment will be completed later this year. Data from the study is expected during thefirst quarter of 2015.
Forward-Looking Information is Subject to Risk and Uncertainty
This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertainties, and include, but are not limited to, statements relating to GTx's clinical trials for enobosarm (GTx-024) and its clinical trial of GTx-758 (Capesaris®). GTx's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks (i) that GTx may not be able to obtain required regulatory approvals to commercialize its product candidates in a timely manner or at all; or (ii) that clinical trials being conducted by GTx may not be completed on schedule, or at all, or may otherwise be suspended or terminated. GTx’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. GTx will continue to need additional funding and may be unable to raise capital when needed, which would force GTx to delay, reduce or eliminate its product candidate development programs and potentially cease operations. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. GTx’s quarterly report on Form 10-Q, which is expected to be filed with the
Condensed Balance Sheets
(in thousands, except share data)
|Cash and cash equivalents||$||11,178||$||14,529|
|Prepaid expenses and other current assets||1,194||442|
|Total current assets||18,452||15,171|
|Property and equipment, net||58||112|
|Intangible and other assets, net||625||322|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Accrued expenses and other current liabilities||2,711||3,759|
|Total current liabilities||3,703||4,567|
|Other long-term liabilities||147||354|
|Commitments and contingencies|
Common stock, ||76||63|
|Additional paid-in capital||490,500||465,981|
|Total stockholders’ equity||15,285||10,684|
|Total liabilities and stockholders’ equity||$||19,135||$||15,605|
Condensed Statements of Operations
(in thousands, except share and per share data)
|Three Months Ended||Six Months Ended|
|Research and development expenses||$||7,894||$||10,139||$||14,254||$||19,753|
|General and administrative expenses||3,052||2,684||5,681||5,707|
|Loss from operations||(10,946||)||(12,823||)||(19,935||)||(25,460||)|
|Other income, net||2||21||4||76|
|Net loss per share:|
|Basic and diluted||$||(0.15||)||$||(0.20||)||$||(0.28||)||$||(0.40||)|
|Weighted average shares outstanding:|
|Basic and diluted||75,433,302||62,994,771||70,997,330||62,929,816|